Biosynth has announced that its Board of Directors has appointed Matt Gunnison as its new CEO, while Kieran Murphy will take the position of Chair.
Matt will succeed Urs Spitz, who will remain on the Board of Directors.
Matt is currently the CEO of Gamma Biosciences, a life sciences investment platform, and will bring nearly 20 years of experience to the table.
Prior to Gamma, Matt held a range of positions in GE Healthcare, with the most recent being as the head of corporate development for the USD $19b division of General Electric Co.
Kieran currently serves as a senior advisor to KKR, and will transition to Biosynth from Gamma Biosciences, where he has served as Chair since 2022.
Mr Murphy will bring decades of corporate leadership and board experience in the life sciences industry to this role.
Previously, he was the former President and CEO of GE Healthcare and GE Healthcare Life Sciences.
Joining Matt and Kieran as Head of Corporate Development for Biosynth is Eric Simpson, previously Vice President at Gamma Biosciences.
Partner at KKR and Head of Europe for KKR’s Health Care Strategic Growth strategy, Kugan Sathiyanandarajah, commented: “We are grateful to Urs for his significant contributions in shaping Biosynth into the innovative and thriving company it is today. We are now excited to welcome Matt as CEO, whose vision and extensive experience will be pivotal in leading the company through its next chapter.”
Matt added: “I am thrilled to join Biosynth at such an exciting time in its journey. The company has built a strong foundation under Urs’s leadership, and I look forward to working with the talented team to further accelerate our growth and innovation. Together, we will continue to deliver critical raw materials and services that drive advancements in the life sciences and make a real impact on global health outcomes,”
Kieran concluded: “It’s a privilege to be appointed Chairman of Biosynth. I am excited to work alongside Matt and the entire team as we chart the course for the company’s continued growth. Biosynth is at the forefront of innovation in the life sciences industry, and I am confident we have the right leadership and vision to drive our success forward,”